Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amicus Therapeutics, Inc. - Common Stock
(NQ:
FOLD
)
9.640
-0.010 (-0.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amicus Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
February 10, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
February 03, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
January 13, 2025
Via
Benzinga
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
January 12, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics
November 12, 2024
Via
Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
November 12, 2024
Via
Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
November 12, 2024
Via
Benzinga
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
December 13, 2024
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
Via
Benzinga
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights
November 07, 2024
Via
Benzinga
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
November 06, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
November 01, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
October 11, 2024
Via
Benzinga
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
May 14, 2024
Via
Benzinga
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
October 28, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
October 17, 2024
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday
October 17, 2024
Via
Benzinga
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
October 17, 2024
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
October 04, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
September 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
September 03, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
August 30, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
August 08, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
June 04, 2024
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
May 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.